文献速递泌尿男性生殖肿瘤

肿瘤微环境转录组分析揭示透明细胞肾细胞癌的不同亚组:来自一项随机III期试验的数据

Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial.
PubMed 文献 · Cancer Discov · 2019-01-08

研究对COMPARZ III期试验中接受一线舒尼替尼或帕唑帕尼治疗的转移性透明细胞肾细胞癌患者进行整合基因组和转录组分析,识别出四个与缓解和生存相关的分子亚组,突变谱、血管生成和巨噬细胞浸润程序是TKI疗效的有力预测因子,且预测因子因TKI类型而异。

要点

  • 基于RNA分析识别出四个与TKI缓解和生存相关的不同分子亚组。
  • 突变谱、血管生成和巨噬细胞浸润程序是TKI治疗结局的有力预测因子。
  • 预测因子因所接受的TKI类型(舒尼替尼或帕唑帕尼)而异。

核心结论

  • 肿瘤微环境的关键血管生成和免疫特征可能影响TKI缓解,这些发现有望为肾细胞癌患者的个体化治疗提供信息。

研究设计与样本

  • COMPARZ III期试验中接受一线舒尼替尼或帕唑帕尼治疗的转移性透明细胞肾细胞癌患者的整合基因组和转录组分析。

主要发现

  • 基于RNA的分析揭示四个与缓解和生存相关的不同分子亚组。
  • 表征这些亚组发现突变谱、血管生成和巨噬细胞浸润程序是TKI治疗结局的有力预测因子。
  • 预测因子因所接受的TKI类型而异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Metastasis remains the main reason for renal cell carcinoma (RCC)-associated mortality. Tyrosine kinase inhibitors (TKI) impart clinical benefit for most patients with RCC, but the determinants of response are poorly understood. We report an integrated genomic and transcriptomic analysis of patients with metastatic clear cell RCC (ccRCC) treated with TKI therapy and identify predictors of response. Patients in the COMPARZ phase III trial received first-line sunitinib or pazopanib with comparable efficacy. RNA-based analyses revealed four distinct molecular subgroups associated with response and survival. Characterization of these subgroups identified mutation profiles, angiogenesis, and macrophage infiltration programs to be powerful predictors of outcome with TKI therapy. Notably, predictors differed by the type of TKI received. Our study emphasizes the clinical significance of angiogenesis and immune tumor microenvironment and suggests that the critical effects its various aspects have on TKI efficacy vary by agent. This has broad implications for optimizing precision treatment of RCC. SIGNIFICANCE: The determinants of response to TKI therapy in metastatic ccRCC remain unknown. Our study demonstrates that key angiogenic and immune profiles of the tumor microenvironment may affect TKI response. These findings have the potential to inform treatment personalization in patients with RCC.This article is highlighted in the In This Issue feature, p. 453.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Hakimi AA, Voss MH, Kuo F, et al. Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial. Cancer Discov. 2019. PMID: 30622105. doi:10.1158/2159-8290.CD-18-0957

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。